The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 21, 2019

Filed:

Feb. 23, 2018
Applicant:

Livepet, Llc, Austin, TX (US);

Inventors:

Ian Mitchell, Bartlesville, OK (US);

Ayyappan Subbiah, Bartlesville, OK (US);

Daniel David Bensimon, Austin, TX (US);

Assignee:

LivePet, LLC, Austin, TX (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 33/44 (2006.01); A61K 47/54 (2017.01); A61P 35/04 (2006.01); A61K 31/015 (2006.01); A61K 31/20 (2006.01); C01B 32/156 (2017.01); C01B 32/152 (2017.01); A61K 47/69 (2017.01);
U.S. Cl.
CPC ...
A61K 47/549 (2017.08); A61K 31/015 (2013.01); A61K 31/20 (2013.01); A61K 33/44 (2013.01); A61K 47/555 (2017.08); A61K 47/6949 (2017.08); A61P 35/04 (2018.01); C01B 32/152 (2017.08); C01B 32/156 (2017.08);
Abstract

In some embodiments, a lipofullerene-saccharide compound and a method of inhibiting and/or ameliorating metastasis of neoplastic cells using said compound is disclosed herein. The lipofullerene-saccharide compound may be used in therapeutically effective doses to inhibit the metastasis of neoplasms in mammals. In some embodiments, the method may include administering to a subject an effective amount of a pharmaceutically acceptable formulation including a lipofullerene-saccharide compound. In some embodiments, the lipofullerene-saccharide compound may be formed by reacting (e.g., coupling) a lipid and a saccharide with a fullerene. In some embodiments, neoplastic cells may include pancreatic cancer cells, prostate cancer cells, lung cancer cells, breast cancer cells, colon cancer cells, and/or brain cancer cells. A significant anti-metastatic effect has been observed on a metastatic nude-mouse model of human pancreatic cancer BxPC-3 cell lines constructed orthotopically as a result of therapeutic treatment with the lipofullerene-saccharide conjugate.


Find Patent Forward Citations

Loading…